EUROAPI SASU (EAPI.PA) Stock Price & Overview

EPA:EAPIFR0014008VX5

Current stock price

1.265 EUR
-0.04 (-2.69%)
Last:

The current stock price of EAPI.PA is 1.265 EUR. Today EAPI.PA is down by -2.69%. In the past month the price decreased by -8.33%. In the past year, price decreased by -48.54%.

EAPI.PA Key Statistics

52-Week Range1.22 - 3.572
Current EAPI.PA stock price positioned within its 52-week range.
1-Month Range1.22 - 1.385
Current EAPI.PA stock price positioned within its 1-month range.
Market Cap
120.921M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.23
Dividend Yield
N/A

EAPI.PA Stock Performance

Today
-2.69%
1 Week
+0.96%
1 Month
-8.33%
3 Months
-42.50%
Longer-term
6 Months -61.48%
1 Year -48.54%
2 Years -57.15%
3 Years -88.39%
5 Years N/A
10 Years N/A

EAPI.PA Stock Chart

EUROAPI SASU / EAPI Daily stock chart

EAPI.PA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to EAPI.PA. When comparing the yearly performance of all stocks, EAPI.PA is a bad performer in the overall market: 97.44% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

EAPI.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to EAPI.PA. While EAPI.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EAPI.PA Earnings

Next Earnings DateJul 28, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

EAPI.PA Forecast & Estimates

13 analysts have analysed EAPI.PA and the average price target is 2.3 EUR. This implies a price increase of 81.42% is expected in the next year compared to the current price of 1.265.

For the next year, analysts expect an EPS growth of 63.82% and a revenue growth -11.29% for EAPI.PA


Analysts
Analysts44.62
Price Target2.3 (81.82%)
EPS Next Y63.82%
Revenue Next Year-11.29%

EAPI.PA Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

EAPI.PA Financial Highlights

Over the last trailing twelve months EAPI.PA reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS decreased by -61.42% compared to the year before.


Income Statements
Revenue(TTM)852.60M
Net Income(TTM)-211.20M
Industry RankSector Rank
PM (TTM) N/A
ROA -16.19%
ROE -26.8%
Debt/Equity 0.08
Chartmill High Growth Momentum
EPS Q2Q%-90.51%
Sales Q2Q%-6.45%
EPS 1Y (TTM)-61.42%
Revenue 1Y (TTM)-7.25%

EAPI.PA Ownership

Ownership
Inst Owners36.18%
Shares95.59M
Float61.77M
Ins Owners0.01%
Short Float %N/A
Short RatioN/A

About EAPI.PA

Company Profile

EAPI logo image EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.

Company Info

IPO: 2022-05-06

EUROAPI SASU

15, rue Traversiere

Paris ILE-DE-FRANCE FR

Employees: 3187

EAPI Company Website

EAPI Investor Relations

Phone: 33189206200

EUROAPI SASU / EAPI.PA FAQ

Can you describe the business of EUROAPI SASU?

EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.


What is the current price of EAPI stock?

The current stock price of EAPI.PA is 1.265 EUR. The price decreased by -2.69% in the last trading session.


What is the dividend status of EUROAPI SASU?

EAPI.PA does not pay a dividend.


What is the ChartMill technical and fundamental rating of EAPI stock?

EAPI.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the analyst forecast for EAPI.PA stock?

13 analysts have analysed EAPI.PA and the average price target is 2.3 EUR. This implies a price increase of 81.42% is expected in the next year compared to the current price of 1.265.


Can you provide the PE ratio for EAPI stock?

EUROAPI SASU (EAPI.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).


Can you provide the market cap for EUROAPI SASU?

EUROAPI SASU (EAPI.PA) has a market capitalization of 120.92M EUR. This makes EAPI.PA a Micro Cap stock.